Nuvalent, Inc. (NUVL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 43.17 |
| Open | 43.18 |
| Bid | 43.49 x 1100 |
| Ask | 45.31 x 1100 |
| Day's Range | 42.40 - 43.71 |
| 52 Week Range | 16.22 - 50.58 |
| Volume | |
| Avg. Volume | 335,495 |
| Market Cap | 2.486B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.78 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NUVL
Related Research
- Nuvalent, Inc.Daily – Vickers Top Buyers & Sellers for 07/12/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 months agoArgus Research
PR NewswireNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.
Simply Wall St.We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. Indeed, Nuvalent ( NASDAQ:NUVL ) stock...
- PR Newswire
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of the Phase 2 portion of ARROS-1, its Phase 1/2 clinical trial of NVL-520 for patients with ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, following alignment with the US Food and Drug Administration (FDA) on a recommended Phase 2 dose (RP2D) of 100 mg daily.
